CBD did not significantly improve gastroparesis symptoms over placebo in a controlled trial
A randomized, controlled trial found 4 weeks of pharmaceutical CBD did not significantly improve symptoms in patients with idiopathic or diabetic gastroparesis compared to placebo.
Quick Facts
What This Study Found
Pharmaceutical CBD treatment for 4 weeks did not produce significant improvements in gastroparesis symptoms compared to placebo. Despite CBD's known effects on gut sensation and inflammation, these did not translate to clinical benefit in this patient population.
Key Numbers
4 weeks of pharmaceutical CBD treatment. Compared to placebo. No significant improvement in gastroparesis symptoms.
How They Did This
Randomized, controlled trial comparing 4 weeks of pharmaceutical CBD versus placebo in patients with idiopathic or diabetic gastroparesis. Multiple symptom and physiological endpoints assessed.
Why This Research Matters
Gastroparesis is a debilitating condition with limited treatment options. This negative trial is important because it tempers expectations about CBD for gastrointestinal conditions despite mechanistic rationale.
The Bigger Picture
Negative trials are essential for building an honest evidence base. While CBD has demonstrated gastrointestinal effects in preclinical studies, this trial shows those effects do not automatically translate to symptom improvement in gastroparesis patients.
What This Study Doesn't Tell Us
Relatively short treatment duration (4 weeks). Specific CBD dose used may not be optimal. Small sample size possible. Gastroparesis symptom measurement is challenging. Does not rule out benefit at different doses or longer treatment durations.
Questions This Raises
- ?Would higher CBD doses or longer treatment produce different results?
- ?Are there gastroparesis subtypes that might respond better to CBD?
Trust & Context
- Key Stat:
- CBD did not outperform placebo for gastroparesis symptoms over 4 weeks
- Evidence Grade:
- Randomized controlled trial with appropriate design. Negative result is informative for clinical decision-making.
- Study Age:
- Published 2023.
- Original Title:
- A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.
- Published In:
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 21(13), 3405-3414.e4 (2023)
- Authors:
- Zheng, Ting, BouSaba, Joelle, Taylor, Ann, Dilmaghani, Saam, Busciglio, Irene, Carlson, Paula, Torres, Monique, Ryks, Michael, Burton, Duane, Harmsen, William Scott, Camilleri, Michael
- Database ID:
- RTHC-05053
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does CBD help gastroparesis?
In this controlled trial, 4 weeks of pharmaceutical CBD did not significantly improve gastroparesis symptoms compared to placebo. While CBD has anti-inflammatory and gut-modulating properties in laboratory studies, these did not translate to clinical benefit in this patient population.
Why did CBD not work for gastroparesis despite lab evidence?
The gap between preclinical promise and clinical results is common in drug development. Gastroparesis is a complex condition with multiple contributing factors, and CBD's effects on isolated gut cells may not address the primary drivers of symptoms in patients. The dose or duration may also have been insufficient.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05053APA
Zheng, Ting; BouSaba, Joelle; Taylor, Ann; Dilmaghani, Saam; Busciglio, Irene; Carlson, Paula; Torres, Monique; Ryks, Michael; Burton, Duane; Harmsen, William Scott; Camilleri, Michael. (2023). A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 21(13), 3405-3414.e4. https://doi.org/10.1016/j.cgh.2023.07.008
MLA
Zheng, Ting, et al. "A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2023. https://doi.org/10.1016/j.cgh.2023.07.008
RethinkTHC
RethinkTHC Research Database. "A Randomized, Controlled Trial of Efficacy and Safety of Can..." RTHC-05053. Retrieved from https://rethinkthc.com/research/zheng-2023-a-randomized-controlled-trial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.